Regenerative Anti-Aging
Cellular support for skin radiance and tone.
BPC-157 + TB-500GHK-Cu Peptide
Peptide therapy · 503A compounded
GHK-Cu peptide, copper tripeptide for skin regeneration and tissue recovery.
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is one of the more interesting molecules in regenerative medicine, a naturally occurring tripeptide that declines measurably with age and has demonstrated meaningful effects on fibroblast activity, collagen synthesis, and gene expression in human tissue studies. Unlike many compounds in the longevity space, GHK-Cu has a credible topical evidence base. Its compounded injectable form is less studied and requires a more conservative interpretation.
What it is
GHK-Cu is a tripeptide composed of glycine, histidine, and lysine, bound to a copper(II) ion. It is produced naturally in human plasma, saliva, and urine, and its levels decline significantly with age, from approximately 200 ng/mL in young adults to around 80 ng/mL by age 60.
In cosmetic dermatology, copper tripeptide-1 (the INCI name) has been used in topical creams and serums for decades. Compounded injectable GHK-Cu represents a more recent application with a smaller evidence base. Genesis Longevity offers both routes, with honest guidance about where the evidence is stronger.
How it works
Collagen and elastin synthesis. GHK-Cu stimulates fibroblast production of collagen types I and III and elastin, two structural proteins that decline with age and UV exposure. It also modulates matrix metalloproteinases (MMPs), shifting the balance toward net collagen preservation.
Antioxidant and anti-inflammatory activity. GHK-Cu upregulates antioxidant enzymes (superoxide dismutase, catalase) and reduces pro-inflammatory cytokines, which may explain its observed wound-healing effects.
Angiogenesis support. GHK-Cu promotes new blood vessel formation via VEGF and FGF-2 upregulation, which may improve nutrient and oxygen delivery to skin and healing tissues.
Gene expression modulation. Research by Pickart et al. documented GHK-Cu's capacity to shift gene expression in skin and other tissues toward a more regenerative pattern, including genes involved in wound healing, DNA repair, and anti-aging biology.
Conditions and use cases
Where GHK-Cu has a clinical role at Genesis.
- Skin aging, wrinkles, elasticity loss, and dullness (topical). Strongest evidence base; human studies document improvements in firmness, fine line depth, and texture.
- Post-procedure skin recovery (topical). Used as an adjunct following laser resurfacing, microneedling, or chemical peels.
- Wound healing support. Cell-culture data support fibroblast activation and angiogenic properties.
- Hair thinning (scalp, compounded). Included in compound protocols as a follicle-supportive adjunct.
- Injectable GHK-Cu for systemic regenerative support. Evidence is preclinical. Offered under informed consent acknowledging this limitation.
Expected timeline
What patients commonly observe.
Week 0 to 2
Tolerability window
Topical: hydration improvement signals begin. Injectable: site reactions are the most common early effect.
Week 2 to 4
Early texture change
Topical: early texture improvement reported. Injectable: no validated clinical timeline.
Month 1 to 3
Topical firmness gains
Topical: improved firmness and reduction in fine line appearance, more even tone.
Month 3 to 6
Maintenance phase
Continued topical use sustains gains. Injectable cycles often run 30 days on, 15 to 30 days off.
Stacks that include this therapy
GHK-Cu peptide appears in these stacks.
Skin Longevity & Glow
Cellular support for skin radiance and tone.
NAD+ InjectionGHK-Cu PeptideOptional: Glutathione Injection
Investment and access
Care plans, not menus.
Genesis Longevity therapies are dispensed only after a complimentary consultation and Good Faith Exam. Schedule yours to receive a personalized plan tailored to your biology and goals.
Side effects
What patients commonly report.
Topical. Mild skin irritation, redness, or itching, particularly at higher concentrations. Contact dermatitis is uncommon.
Compounded injectable. Injection site reactions including redness and induration. Theoretical copper toxicity (nausea, abdominal pain) at excessive or prolonged doses, unlikely at standard compounded doses but monitored via serum copper.
Contraindications
Who should not use this therapy.
Show contraindications
Wilson disease or other copper metabolism disorders. Risk of copper accumulation.
Pregnancy and breastfeeding. Insufficient safety data.
Active malignancy. Theoretical concern given GHK-Cu's angiogenic properties.
Known copper allergy (topical and injectable).
Pairs well with
Therapies that complement this protocol.
- 503A compounded
NAD+ Injection
Cellular energy, cognitive function, and systemic antiaging support.
Moderate evidence - Research peptide
BPC-157
Tissue repair, inflammation reduction, and gut lining integrity.
Emerging evidence - 503A compounded
Glutathione Injection
Antioxidant and detoxification support.
Moderate evidence
Frequently asked
Frequently asked questions about GHK-Cu peptide.
No. GHK-Cu is recognized as a cosmetic ingredient for topical use. Compounded injectable forms are 503A preparations, not FDA-approved drugs, and lack large human RCTs establishing clinical efficacy.
Topical GHK-Cu has the strongest evidence base in humans, particularly for skin texture, firmness, and fine lines. Injectable use is more speculative, primarily supported by preclinical data, and is appropriate only for patients who understand and accept that limitation.
At standard topical doses, copper overload is very unlikely. With prolonged compounded injection use, monitoring serum copper and ceruloplasmin is reasonable precaution, especially in patients with any liver concern.
GHK-Cu targets fibroblast collagen synthesis and MMP modulation. Other skin peptides such as Matrixyl/palmitoyl tripeptide-1 target similar pathways with different mechanisms. GHK-Cu has stronger human cosmetic data than most competing peptide ingredients.
Topical GHK-Cu is generally compatible with most cosmetic actives. Some sources suggest not layering it directly with high-concentration vitamin C on the same application (copper may interact with oxidized ascorbic acid), though this concern is modest at cosmetic concentrations. Your provider or aesthetician can advise on sequencing.
Topical: 0.05 to 2 percent copper tripeptide-1 in cream or serum, applied once or twice daily. Compounded injectable: typically 1 to 2 mg subcutaneous daily or 3 to 5 days per week, often cycled (30 days on, 15 to 30 days off).
Sources
Citations & references
- [1]Innerbody Research, GHK-Cu Peptide overview. Source
- [2]Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin. PMC4508379.
- [3]Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide. PMC6073405.
- [4]Pickart L et al. GHK-Cu tripeptide review. PubMed 25731775.
- [5]SL Compounding Pharmacy, GHK-Cu injection monograph. Source
- [6]Prime Journal, Copper Tripeptide GHK-Cu and Regenerative Aesthetics. Source
Status & disclosures
- FDA status: cosmetic ingredient · injectable not FDA-approved
- Topical GHK-Cu is recognized as a cosmetic ingredient. Compounded injectable GHK-Cu is a 503A preparation, not an FDA-approved drug.
- 503A compounded preparation
- Compounded injectable GHK-Cu is prepared by licensed 503A pharmacies under U.S. FDA regulations. Genesis sources from regulated compounders.
- Provider supervision required
- Compounded injectable use requires a Good Faith Exam and provider consultation.
Next step
Talk to a Genesis provider about GHK-Cu peptide.
Schedule a consultation. Physician-led, evidence-graded.
Or keep reading: See the Skin Longevity & Glow stack